American Association for Cancer Research--100th Annual Meeting. HDAC inhibitors, proteasome inhibitors and vascular disrupting agents. 18-22 April 2009, Denver, CO, USA.
Mitra
Anirban P
AP
University of Southern California, Keck School of Medicine, Department of Pathology, Los Angeles, CA 90033, USA. amitra@usc.edu
D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D016503:Drug Delivery Systems; D015507:Drugs, Investigational / Q000494:pharmacology / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D056572:Histone Deacetylase Inhibitors / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D061988:Proteasome Inhibitors
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D015507:Drugs, Investigational; D004791:Enzyme Inhibitors; D056572:Histone Deacetylase Inhibitors; D061988:Proteasome Inhibitors